In the next two to three months a drug in a first in class 60 billion dollar market proven up for safety in first cohort already clears remaining 4 cohorts, proven for mechanism of action from NONO-42 and AGN in neuroprotection for inhibiting calcium influx into neurons, only drug in the world capable of effectively targeting secondary brain injury, primary brain injury and cardiovascular protection all at once in stroke in a 60 billion dollar unmet space valued at a19 million market cap while peers trade at 80-130 million market caps. Just funny the time will come for us Kyriaco
NYR Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)